|1.||Respiratory Insufficiency (Respiratory Failure)
|2.||Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease)
|3.||Duchenne Muscular Dystrophy (Muscular Dystrophy, Becker)
|4.||Deglutition Disorders (Dysphagia)
|5.||Congenital Abnormalities (Deformity)
|1.||Lofaso, Frédéric: 9 articles (09/2014 - 01/2003)|
|2.||Orlikowski, David: 7 articles (09/2014 - 02/2007)|
|3.||Bach, John R: 7 articles (03/2013 - 06/2002)|
|4.||Chevret, S: 7 articles (08/2008 - 01/2000)|
|5.||Fauroux, Brigitte: 6 articles (09/2014 - 09/2008)|
|6.||Prigent, Hélène: 6 articles (01/2014 - 01/2003)|
|7.||Mitchell, J D: 6 articles (01/2012 - 01/2002)|
|8.||Russell, Aaron P: 5 articles (05/2015 - 10/2007)|
|9.||Lejaille, Michèle: 5 articles (05/2013 - 01/2003)|
|10.||Boles, Richard G: 5 articles (02/2007 - 08/2003)|
01/01/2002 - "This is because of the widespread use of creatine by athletes, on the one hand, and to some promising results regarding its therapeutic potential in neuromuscular disease on the other. "
01/01/2013 - "On 11 September 2012, we searched the Cochrane Neuromuscular Disease Group Specialized Register, CENTRAL (2012, Issue 9 in The Cochrane Library), MEDLINE (January 1966 to September 2012) and EMBASE (January 1980 to September 2012) for randomised controlled trials (RCTs) of creatine used to treat muscle diseases. "
01/01/2012 - "We searched the Cochrane Neuromuscular Disease Group Specialized Register (16 July 2012), CENTRAL (2012, issue 7 in the Cochrane Library), MEDLINE (January 1966 to July 2012) and EMBASE (January 1980 to July 2012) for any trial involving creatine in the treatment of ALS. We also contacted experts in the field for any additional studies. "
01/01/2011 - "We searched the Cochrane Neuromuscular Disease Group Specialized Register (4 October 2010), the Cochrane Central Register of Controlled Trials (11 October 2010, Issue 4, 2010 in The Cochrane Library), MEDLINE (January 1966 to September 2010) and EMBASE (January 1980 to September 2010) for randomised controlled trials (RCT) of creatine used to treat muscle diseases. "
01/01/2010 - "We searched the Cochrane Neuromuscular Disease Group Trials Specialized Register, the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library issue 4, 2009), MEDLINE and EMBASE in October 2009 for any trial involving creatine in the treatment of ALS. "
08/15/1994 - "54 consecutive patients with various immune-related neuromuscular diseases participating in ongoing therapeutic trials of high-dose (2 g/kg) intravenous immunoglobulin. "
10/01/1988 - "In the present study immunoglobulins from 4 of 8 ALS patients induced a significant increase in spontaneous quantal transmitter release as monitored by miniature end-plate potential (MEPP) frequency in mouse phrenic nerve-diaphragm preparations at 23 degrees C, whereas immunoglobulins from normal individuals and from patients with other neuromuscular diseases had no effect. "
08/01/2013 - "Long-term day-case treatment of peripheral neuromuscular disease with intravenous immunoglobulin: the practice of a regional day-case service in Preston, Lancashire."
03/01/2009 - "Intravenous immunoglobulin for neuromuscular disease: costs, benefits and reimbursement."
06/01/2004 - "The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: evidence-based indications and safety profile."
06/01/1991 - "Predictive value of anti-GM1 ganglioside antibodies in neuromuscular diseases: a study of 180 sera."
01/01/2012 - "On the other hand, it has been observed that anti-TNF-α antibodies may trigger the appearance of autoimmune neuromuscular diseases. "
12/01/2004 - "Neuromuscular diseases associated with antigliadin antibodies. "
12/01/1997 - "Estimation of circulating antigliadin antibodies should be considered in all patients with neuromuscular disease of otherwise obscure aetiology."
02/01/1997 - "The finding also supports a possible pathogenic role for the previously reported, high titer, high affinity, inhibitory AChE antibodies in the neuromuscular disease."
|4.||Intravenous Immunoglobulins (IVIG)FDA Link
05/19/2004 - "To systematically review the current status of the treatment of autoimmune neuromuscular diseases with IVIG, with emphasis on controlled trials. "
01/01/1993 - "We will present current experience with IVIG in the above-mentioned autoimmune neuromuscular diseases, and we will stress the need for long-term controlled studies. "
08/01/2013 - "Neuromuscular disease is one of the most common indications for the use of intravenous immuno-globulin (IVIG). "
06/01/2012 - "Neuromuscular disease: IVIg for neuromuscular disease-effective but expensive."
07/01/2010 - "IVIG is generally well tolerated and only rarely associated with serious adverse events, but lyophilized forms of IVIG may be associated with greater prevalence of adverse events in patients with neuromuscular diseases."
08/01/2000 - "In cases from whom frozen muscle sections cannot be obtained, immunohistochemical dystrophin analysis using the Catalyzed Signal Amplification system will be beneficial for the diagnosis and the screening of neuromuscular diseases."
01/01/2005 - "In this study, therefore, we examined how two neuromuscular diseases, dystrophin-deficiency and laminin-alpha2-deficiency, altered the proliferation and composition of different subsets of muscle-derived mononucleate cells. "
02/01/2014 - "Dystrophinopathies are X-linked recessive neuromuscular diseases caused by mutations in the dystrophin gene. "
07/01/2010 - "The disease is an X-linked neuromuscular diseases typically caused by disrupting (DMD) or non-disrupting (BMD) the reading frame in the dystrophin (DMD) gene. "
03/01/2002 - "We studied the expression of dystrophin in skin biopsy samples from 19 patients with neuromuscular diseases. "
01/01/2012 - "Clinical trials performed to evaluate the efficacy of monoclonal antibodies in neuromuscular disease are very limited and of reduced size. "
01/01/2012 - "Monoclonal antibodies could be an effective alternative treatment in autoimmune neuromuscular diseases, but the favourable responses observed need to be confirmed by means of controlled clinical trials with a sufficient number of patients."
06/03/1999 - "We investigated the possible role of SMN in normal and abnormal human muscle by immunostaining biopsies of 20 patients with various neuromuscular diseases using monoclonal antibodies against SMN. "
11/01/2012 - "Both monoclonal antibodies to myostatin and a soluble receptor decoy to its high affinity receptor have been used in clinical trials of neuromuscular diseases and while there have been efficacy signals with the latter approach there have also been safety issues. "
07/01/1993 - "The dystrophin test was performed on skeletal muscle specimens from 81 cases with various neuromuscular diseases by using two new monoclonal antibodies. "
02/01/2000 - "The present study shows that in patients with neuromuscular disease, elastic load and respiratory muscle weakness are responsible for a rapid and shallow breathing pattern leading to chronic CO(2) retention."
01/01/2012 - "The nerve-muscle co-culture can also be performed with human muscle cells isolated from patients suffering from muscle or neuromuscular diseases, and thus can be used as a screening tool for candidate drugs. "
07/01/2000 - "Since the identification of Neospora caninum in 1984 as a parasite separate from Toxoplasma gondii by Bjerkas et al., and its subsequent characterization and classification in 1988 by Dubey and co-workers, this parasite has attracted increasing attention, primarily as an important causative agent of abortion in cattle and neuromuscular disease in dogs, but also as a complementary model system to T. "
02/01/2000 - "Mechanism of CO(2) retention in patients with neuromuscular disease."
12/01/2006 - "The use of short-acting anaesthetics, drugs to reduce blood loss, experienced spinal anaesthetists and the availability of intensive care support are all essential for a good outcome in patients with neuromuscular disease and cardiopulmonary co-morbidity."
01/01/1995 - "Compared with DMD cases and non-neuromuscular disease controls, FCMD cases showed a reduction of total gangliosides, and an abnormal, immature ganglioside pattern in the cerebral gray and white matter. "
04/01/1994 - "Despite these findings there is still little evidence that treatment with parenteral gangliosides in humans can be effective in peripheral neuropathies or other neuromuscular diseases. "
11/01/1988 - "We report three 12-month, double-blind, three-phase studies comparing the effect of placebo and 40 mg and 100 mg IM daily of purified bovine brain gangliosides (Cronassial) in chronic neuromuscular diseases. "
10/01/1995 - "The expression of neutral glycosphingolipids (GSLs) and gangliosides was investigated in cryosections of normal mouse skeletal muscle and in muscle of mice with neuromuscular diseases using indirect immunofluorescence microscopy. "
10/01/1995 - "Immunohistological analyses of neutral glycosphingolipids and gangliosides in normal mouse skeletal muscle and in mice with neuromuscular diseases."
|9.||salicylhydroxamic acid (SHAM)IBA
01/01/2013 - "A systematic review of this literature is needed to determine the effectiveness of RMT (either inspiratory or expiratory muscle training) on pulmonary function, dyspnoea, respiratory complications, respiratory muscle strength, and quality of life for people with cervical SCI. To evaluate the efficacy of RMT versus standard care or sham treatments in people with cervical SCI. We searched the Cochrane Injuries and Cochrane Neuromuscular Disease Groups' Specialised Register, the Cochrane Central Register of Controlled Trials (CENTRAL) (2012, Issue 1), MEDLINE, EMBASE, CINAHL, ISI Web of Science, PubMed, and clinical trials registries (Australian New Zealand Clinical Trials Registry, ClinicalTrials, Controlled Trials metaRegister) on 5 to 8 March 2013. "
|10.||Acetylcholine (Acetylcholine Chloride)FDA Link
01/01/2015 - "Since facilitation by the methanolic fraction involved enhanced acetylcholine release, use of this fraction could be potentially beneficial in neuromuscular diseases and in the reversal of residual paralysis in the post-operative period or after local anaesthesia. "
05/01/2014 - "Extensive research on acetylcholine and its function has provided us with important options to treat the formerly intractable neuromuscular disease myasthenia gravis (MG). "
01/01/2007 - "Myasthenia gravis (MG) is a disabling neuromuscular disease in which autoimmune responses against acetylcholine receptor (AChR), especially against the alpha chain of AChR, cause a postsynaptic defect. "
08/01/1994 - "C57BL/6 (B6) mice develop a neuromuscular disease, experimental autoimmune myasthenia gravis (EAMG), after two or more immunizations with Torpedo californica acetylcholine receptor (AChR). "
11/01/1980 - "On the other hand, the amount and distribution of acetylcholine receptor in other neuromuscular diseases was well preserved, even at the endplates denuded of their nerve terminals in amyotrophic lateral sclerosis (ALS) cases."
|1.||Artificial Respiration (Mechanical Ventilation)
02/01/2015 - "The timed inspiratory effort: a promising index of mechanical ventilation weaning for patients with neurologic or neuromuscular diseases."
01/01/2015 - "Home mechanical ventilation in childhood-onset hereditary neuromuscular diseases: 13 years' experience at a single center in Korea."
02/01/2012 - "Medical record review was conducted retrospectively of patients with neuromuscular diseases who had started home mechanical ventilation between June 2008 and May 2010. "
07/01/2011 - "Patients with chronic neuromuscular disease represent less than 10% of those receiving mechanical ventilation in the intensive care unit (ICU). "
12/01/2008 - "We describe the experience of parents caring for children with neuromuscular disease (NMD) on home mechanical ventilation (HMV). "
|2.||Chest Wall Oscillation
12/01/2010 - "Correspondence on ''safety, tolerability, and efficacy of high-frequency chest wall oscillation in pediatric patients with cerebral palsy and neuromuscular diseases: an exploratory randomized controlled trial''."
07/01/2010 - "Safety, tolerability, and efficacy of high-frequency chest wall oscillation in pediatric patients with cerebral palsy and neuromuscular diseases: an exploratory randomized controlled trial."
12/01/2013 - "For adult and pediatric patients with neuromuscular disease, respiratory muscle weakness, or impaired cough, 1) cough assist techniques should be used in patients with neuromuscular disease, particularly when peak cough flow is < 270 L/min; CPT, positive expiratory pressure, intrapulmonary percussive ventilation, and high-frequency chest wall compression cannot be recommended, due to insufficient evidence. "
07/01/2010 - "A prospective, randomized, controlled trial of high-frequency chest wall oscillation and standard chest physiotherapy was performed in participants with neuromuscular disease or cerebral palsy. "
07/01/2010 - "High-frequency chest wall oscillation is used in cystic fibrosis but tolerability and safety data in cerebral palsy and neuromuscular disease are limited. "
11/01/2014 - "Frequency of VAP was 6.03 % with neuromuscular disease, histamine-2 receptor blockers, tracheostomy and positive blood culture being risk factors for VAP."
11/01/2014 - "Neuromuscular disease (P = 0.005), histamine-2 receptor blockers (P = 0.0001), tracheostomy (P = 0.0001), and positive blood culture growth (P = 0.0008) were found to be significantly associated with VAP (univariate analysis). "
01/01/2014 - "In the last 20 years, research efforts have been focused on the use of non-invasive ventilation (NIV) as a mean of avoiding tracheostomy in patients affected by neuromuscular diseases (NMD). "
09/01/2013 - "[What a tracheostomy changes in a child with a neuromuscular disease]."
12/01/2010 - "Among the home-ventilation patients, the majority had neuromuscular diseases, were < 65 years old, and were ventilated via tracheostomy tube. "
|4.||Positive-Pressure Respiration (PEEP)
11/01/2006 - "[Non-invasive positive pressure ventilation for neuromuscular diseases. "
11/01/2006 - "[Searching the literature for non-invasive positive pressure ventilation for neuromuscular diseases]."
11/01/2006 - "[Non-invasive positive pressure ventilation for neuromuscular diseases. "
01/01/2006 - "The use of noninvasive positive pressure ventilation (NPPV) is increasingly accepted as a treatment of respiratory problems in patients with neuromuscular disease. "
02/01/2004 - "Outcome of non-invasive positive pressure ventilation in paediatric neuromuscular disease."
06/01/2013 - "Three studies evaluated the effectiveness of NIV during placement of percutaneous endoscopic gastrostomy in patients with neuromuscular diseases. "
04/01/2010 - "Simplified open gastrostomy can be performed safely for patients with neuromuscular disease with resulting improvements in both longevity and quality of life."
01/01/2010 - "Open gastrostomy for noninvasive ventilation users with neuromuscular disease."
05/01/2007 - "Gastrostomy seems to have a substantial positive impact in patients with neuromuscular disease and feeding difficulties."
09/01/2002 - "Percutaneous endoscopic gastrostomy (PEG) is a simple and reliable method, but there are few data about its use in pediatric forms of neuromuscular diseases (NMD). "